Literature DB >> 12746360

Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities.

Andrew Rosenblum1, Herman Joseph, Chunki Fong, Steven Kipnis, Charles Cleland, Russell K Portenoy.   

Abstract

CONTEXT: Little is known about the prevalence and characteristics of chronic pain among patients with different types of chemical dependency.
OBJECTIVES: To estimate the prevalence and to examine the characteristics of chronic severe pain in chemically dependent populations receiving methadone maintenance or inpatient residential treatment. DESIGN, SETTING, AND PARTICIPANTS: Representative samples of 390 patients from 2 methadone maintenance treatment programs (MMTPs) and 531 patients from 13 short-term residential substance abuse treatment (inpatient) programs, all in New York State, were surveyed in late 2000 and early 2001. MAIN OUTCOME MEASURE: Prevalence of chronic severe pain, defined as pain that persisted for more than 6 months and was of moderate to severe intensity or that significantly interfered with daily activities.
RESULTS: Chronic severe pain was experienced by 37% of MMTP patients (95% confidence interval [CI], 32%-41%) and 24% of inpatients (95% CI, 20%-28%; P =.03). Pain of any type or duration during the past week was reported by 80% of MMTP patients and 78% of inpatients. Among those with chronic severe pain, 65% of MMTP patients and 48% of inpatients reported high levels of pain-related interference in physical and psychosocial functioning. Among MMTP patients, correlates of chronic pain in a multivariate model were age (odds ratio [OR], 2.08; 95% CI, 1.17-3.70), chronic illness (OR, 1.88; 95% CI, 1.07-3.29), lifetime psychiatric illness (OR, 1.77; 95% CI, 1.06-2.97), psychiatric distress (OR, 1.63; 95% CI, 1.22-2.18), and time in treatment (OR, 2.23; 95% CI, 1.06-4.68). Among inpatients, the correlates of chronic pain were race (blacks vs whites: OR, 0.52; 95% CI, 0.31-0.90; Hispanics vs whites: OR, 0.48; 95% CI, 0.24-0.95), drug craving (OR, 2.78; 95% CI, 1.54-5.02), chronic illness (OR, 2.17; 95% CI, 1.37-3.43), and psychiatric distress (OR, 1.36; 95% CI, 1.03-1.81). Among those with chronic severe pain, inpatients were significantly more likely than MMTP patients to have used illicit drugs, as well as alcohol, to treat their pain complaint (51% vs 34%, P =.005) but were less likely to have been prescribed pain medications (52% vs 67%, P =.01).
CONCLUSIONS: Chronic severe pain is prevalent among patients in substance abuse treatment, especially MMTP patients. Pain is associated with functional impairment and correlates of pain vary with the population. Self-medication for pain with psychoactive drugs appears especially problematic among substance users who enroll in drug-free treatment programs. Substance abuse treatment programs need to develop comprehensive and structured pain management programs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746360     DOI: 10.1001/jama.289.18.2370

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  179 in total

Review 1.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

2.  Physician introduction to opioids for pain among patients with opioid dependence and depressive symptoms.

Authors:  Judith I Tsui; Debra S Herman; Malyna Kettavong; Daniel Alford; Bradley J Anderson; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2010-08-19

3.  Pain characteristics and pain catastrophizing in incarcerated women with chronic pain.

Authors:  Beth D Darnall; Elizabeth Sazie
Journal:  J Health Care Poor Underserved       Date:  2012-05

4.  Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; Brian Garnet; Dipa Joshi; Andrew Rosenblum; Richard S Schottenfeld
Journal:  J Pain       Date:  2010-06-20       Impact factor: 5.820

5.  Associations Between Physical Pain, Pain Management, and Frequency of Nonmedical Prescription Opioid Use Among Young Adults: A Sex-specific Analysis.

Authors:  Tristan I Evans; Elliott J Liebling; Traci C Green; Scott E Hadland; Melissa A Clark; Brandon D L Marshall
Journal:  J Addict Med       Date:  2017 Jul/Aug       Impact factor: 3.702

6.  Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; Margaret L Griffin; R Kathryn McHugh; Deborah Haller; Petra Jacobs; John Gardin; Dan Fischer; Kristen D Rosen
Journal:  J Subst Abuse Treat       Date:  2014-04-04

7.  Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.

Authors:  Declan T Barry; Christopher J Cutter; Mark Beitel; Robert D Kerns; Christopher Liong; Richard S Schottenfeld
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

8.  Prescription opioid use among addictions treatment patients: nonmedical use for pain relief vs. other forms of nonmedical use.

Authors:  Amy S B Bohnert; Anna Eisenberg; Lauren Whiteside; Amanda Price; Sean Esteban McCabe; Mark A Ilgen
Journal:  Addict Behav       Date:  2012-11-23       Impact factor: 3.913

9.  Withdrawal-associated injury site pain prevalence and correlates among opioid-using people who inject drugs in Vancouver, Canada.

Authors:  Launette Marie Rieb; Kora DeBeck; Kanna Hayashi; Evan Wood; Ekaterina Nosova; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2020-08-18       Impact factor: 4.492

10.  Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications.

Authors:  Joseph L Goulet; Cynthia Brandt; Stephen Crystal; David A Fiellin; Cynthia Gibert; Adam J Gordon; Robert D Kerns; Stephen Maisto; Amy C Justice
Journal:  Med Care       Date:  2013-03       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.